Andrew D. Mesecar

16.8k total citations · 1 hit paper
167 papers, 11.6k citations indexed

About

Andrew D. Mesecar is a scholar working on Molecular Biology, Infectious Diseases and Computational Theory and Mathematics. According to data from OpenAlex, Andrew D. Mesecar has authored 167 papers receiving a total of 11.6k indexed citations (citations by other indexed papers that have themselves been cited), including 105 papers in Molecular Biology, 36 papers in Infectious Diseases and 26 papers in Computational Theory and Mathematics. Recurrent topics in Andrew D. Mesecar's work include SARS-CoV-2 and COVID-19 Research (33 papers), Computational Drug Discovery Methods (26 papers) and Protein Structure and Dynamics (16 papers). Andrew D. Mesecar is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (33 papers), Computational Drug Discovery Methods (26 papers) and Protein Structure and Dynamics (16 papers). Andrew D. Mesecar collaborates with scholars based in United States, China and Japan. Andrew D. Mesecar's co-authors include Susan C. Baker, Kiira Ratia, Bernard D. Santarsiero, Yahira M. Báez-Santos, Aimee L. Eggler, Sarah E. St. John, John M. Pezzuto, Richard B. van Breemen, Arun K. Ghosh and Barry Stoddard and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

Andrew D. Mesecar

164 papers receiving 11.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds

2014 621 citations Yahira M. Báez-Santos, Sarah E. St. John et al. Antiviral Research profile →

Peers

Countries citing papers authored by Andrew D. Mesecar

Since Specialization

Citations

This map shows the geographic impact of Andrew D. Mesecar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew D. Mesecar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew D. Mesecar more than expected).

Fields of papers citing papers by Andrew D. Mesecar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew D. Mesecar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew D. Mesecar. The network helps show where Andrew D. Mesecar may publish in the future.

Co-authorship network of co-authors of Andrew D. Mesecar

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew D. Mesecar. A scholar is included among the top collaborators of Andrew D. Mesecar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew D. Mesecar. Andrew D. Mesecar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	pH-dependent reaction triggering in PmHMGR crystals for time-resolved crystallography 2024 ·Biophysical Journal ·(unknown), C.N. Steussy, Anthony R. Rosales, (unknown), Tim Schmidt, Paul Helquist, Olaf Wiest, Andrew D. Mesecar, Aina E. Cohen, Cynthia V. Stauffacher	2
2	Development of a sensitive microplate assay for characterizing RNA methyltransferase activity: Implications for epitranscriptomics and drug development 2023 ·Journal of Biological Chemistry ·(unknown), (unknown), (unknown), Emma K. Lendy, (unknown), (unknown), Richard T. Pomerantz, Andrew D. Mesecar, Humaira Gowher	0
3	Desorption Electrospray Ionization Mass Spectrometry Assay for Label‐Free Characterization of SULT2B1b Enzyme Kinetics 2022 ·ChemMedChem ·(unknown), Nicolás M. Morato, (unknown), R. Graham Cooks, Andrew D. Mesecar	25
4	Mn ²⁺ coordinates Cap-0-RNA to align substrates for efficient 2′- O -methyl transfer by SARS-CoV-2 nsp16 2021 ·Science Signaling ·G. Minasov, Mónica Rosas‐Lemus, L. Shuvalova, Nicole L. Inniss, J.S. Brunzelle, Courtney M. Daczkowski, Paul Hoover, Andrew D. Mesecar, K.J.F. Satchell	20
5	Chloropyridinyl Esters of Nonsteroidal Anti-Inflammatory Agents and Related Derivatives as Potent SARS-CoV-2 3CL Protease Inhibitors 2021 ·Molecules ·Arun K. Ghosh, Dana Shahabi, Monika Yadav, (unknown), Brandon J. Anson, Emma K. Lendy, Connie C. Bonham, Devika Sirohi, Carlos A. Brito-Sierra, Shin-ichiro Hattori, Richard Kühn, Hiroaki Mitsuya, Andrew D. Mesecar	11
6	Cholesterol Sulfotransferase SULT2B1b Modulates Sensitivity to Death Receptor Ligand TNFα in Castration-Resistant Prostate Cancer 2019 ·Molecular Cancer Research ·Renee E. Vickman, Jiang Yang, Nadia A. Lanman, Gregory M. Cresswell, (unknown), Chi Zhang, R. W. Doerge, Scott A. Crist, Andrew D. Mesecar, Chang‐Deng Hu, Timothy L. Ratliff	8
7	Computational modeling of the bat HKU4 coronavirus 3CL^pro inhibitors as a tool for the development of antivirals against the emerging Middle East respiratory syndrome (MERS) coronavirus 2017 ·Journal of Molecular Recognition ·Areej Abuhammad, (unknown), Brandon J. Anson, Andrew D. Mesecar, Mutasem O. Taha	21
8	Structural Insights into the Interaction of Coronavirus Papain-Like Proteases and Interferon-Stimulated Gene Product 15 from Different Species 2017 ·Journal of Molecular Biology ·Courtney M. Daczkowski, John V. Dzimianski, (unknown), (unknown), Andrew D. Mesecar, Scott D. Pegan	76
9	Cholesterol Sulfonation Enzyme, SULT2B1b, Modulates AR and Cell Growth Properties in Prostate Cancer 2016 ·Molecular Cancer Research ·Renee E. Vickman, Scott A. Crist, (unknown), Lívia S. Eberlin, R. Graham Cooks, Grant N. Burcham, Kimberly K. Buhman, Chang-Deng Hu, Andrew D. Mesecar, Liang Cheng, Timothy L. Ratliff	23
10	Probing the structural requirements of non-electrophilic naphthalene-based Nrf2 activators 2015 ·European Journal of Medicinal Chemistry ·Atul D. Jain, Haranatha R. Potteti, (unknown), Laura J. Kingsley, (unknown), (unknown), Hyun Lee, Aleksej Krunić, Andrew D. Mesecar, Sekhar P. Reddy, Terry W. Moore	86
11	Ligand-induced Dimerization of Middle East Respiratory Syndrome (MERS) Coronavirus nsp5 Protease (3CLpro) 2015 ·Journal of Biological Chemistry ·Sakshi Tomar, Melanie L. Johnston, Sarah E. St. John, Heather L. Osswald, Prasanth R. Nyalapatla, Lake N. Paul, Arun K. Ghosh, Mark R. Denison, Andrew D. Mesecar	111
12	X-ray structure and inhibition of the feline infectious peritonitis virus 3C-like protease: Structural implications for drug design 2015 ·Bioorganic & Medicinal Chemistry Letters ·Sarah E. St. John, (unknown), Prasanth R. Nyalapatla, Heather L. Osswald, Arun K. Ghosh, Andrew D. Mesecar	16
13	The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds breakdown → 2014 ·Antiviral Research ·Yahira M. Báez-Santos, Sarah E. St. John, Andrew D. Mesecar	621
14	Structure-based design, synthesis and biological evaluation of novel β-secretase inhibitors containing a pyrazole or thiazole moiety as the P3 ligand 2014 ·Bioorganic & Medicinal Chemistry Letters ·Arun K. Ghosh, Margherita Brindisi, (unknown), Xiaoming Xu, Xiangping Huang, Thippeswamy Devasamudram, Geoffrey Bilcer, (unknown), Gerald Koelsch, Andrew D. Mesecar, Jordan Tang	18
15	Synthesis of 3-(3-aryl-pyrrolidin-1-yl)-5-aryl-1,2,4-triazines that have antibacterial activity and also inhibit inorganic pyrophosphatase 2013 ·Bioorganic & Medicinal Chemistry ·Wei Lv, Biplab Banerjee, (unknown), Mohamed N. Seleem, (unknown), Maha I. Hamed, Baojie Wan, Scott G. Franzblau, Andrew D. Mesecar, Mark Cushman	31
16	MERS-CoV papain-like protease has deISGylating and deubiquitinating activities 2013 ·Virology ·Anna M. Mielech, Andy Kilianski, Yahira M. Báez-Santos, Andrew D. Mesecar, Susan C. Baker	179
17	Severe Acute Respiratory Syndrome Coronavirus Papain-Like Protease Ubiquitin-Like Domain and Catalytic Domain Regulate Antagonism of IRF3 and NF-κB Signaling 2009 ·Journal of Virology ·Matthew B. Frieman, Kiira Ratia, Robert E. Johnston, Andrew D. Mesecar, Ralph S. Baric	293
18	A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication 2008 ·Proceedings of the National Academy of Sciences ·Kiira Ratia, Scott D. Pegan, Jun Takayama, Katrina Sleeman, Melissa M. Coughlin, Surendranath Baliji, Rima Chaudhuri, Wentao Fu, Bellur S. Prabhakar, Michael E. Johnson, Susan C. Baker, Arun K. Ghosh, Andrew D. Mesecar	366
19	GABAergic phthalide dimers from Angelica sinensis (Oliv.) Diels 2006 ·Phytochemical Analysis ·Shixin Deng, Shao‐Nong Chen, (unknown), Zaijie Jim Wang, Dejan Nikolić, Richard B. van Breemen, Bernard D. Santarsiero, Andrew D. Mesecar, Harry H. S. Fong, Norman R. Farnsworth, Guido F. Pauli	26
20	Activity-guided isolation of cytotoxic constituents from the bark of Aglaia crassinervia collected in Indonesia 2005 ·Bioorganic & Medicinal Chemistry ·Bao-Ning Su, Heebyung Chai, Qiuwen Mi, Soedarsono Riswan, Leonardus B.S. Kardono, Johar J. Afriastini, Bernard D. Santarsiero, Andrew D. Mesecar, Norman R. Farnsworth, Geoffrey A. Cordell, Steven M. Swanson, A. Douglas Kinghorn	66

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact